ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

Surveillance Following Surgery Sufficient in Stage I Seminoma

May 31, 2013

In Brief: CCOP Formats To Be Available For Help In Writing Applications; Gale On Videotape

August 8, 1986

NCAB Review Of Cancer Control Program Finds It Has Made Substantial Progress But Has Problems

October 13, 1978

“We Will Move Forward With Bold Expectations,” NCI Director Says

October 2, 1998

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005